NEW YORK (GenomeWeb) – Genentech will sequence the whole genomes of 3,000 people from 23andMe's Parkinson's disease community in an effort to identify drug targets, the companies announced today.

Under the terms of the deal, 23andMe will be able to conduct additional research on the generated data once the project is completed. Additionally, 23andMe can share the data, scrubbed of patients' identifying information, with other researchers. Only data from 23andMe customers who have consented to participate in the research will be shared, 23andMe said in a statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Using DNA to sketch crime victims might not be a great idea, the NYTimes says.

Science has its own problem with sexual harassment. What do we do with the research these abusers produce, Wired asks.

Senate Republicans led by Senator Rand Paul (R-KY) are trying to change how the government funds basic research, reports ScienceInsider.

In Science this week: combining genomics and ecology to better understand the effects of natural selection on evolution, and more.